TABLE 1:

Ruxolitinib 2-Compartment PK models with V₁ and V₂ normalized to mean body weights (kg).

	Model III		Model IV (separated CL/F by EFV status)
Sig. digits	3.7		3.6
MVOF	2,793		2,769
Parameter	Typical value	RSE (%)	Typical value	RSE (%)
CL/F [L/hr]	14.7	6.8	12.9	8.3
			(with EFV) 22.5	8.8
V1/F [L]	59.6	7.0	47.8	18.9
Q/F [L/hr]	4.94	30	12.0	25.2
V2/F[L]	7.88	49	20.7	6.0
Ka [1/hr]	7.05	35	1.82	43.2
F (fixed)	1		1
Error structure	ω2 (CV)	RSE of ω2 (shrinkage)	ω2 (CV)	RSE of ω2 (shrinkage)
$II{V}_{CL/F}$	0.1182 (35.4%)	0.032 (8%)	0.0649 (25.9%)	0.02439 (9%)
$II{V}_{V_1}$	0.0607 (25.0%)	0.042 (31%)	NE
$II{V}_{V_2}$	2.427 (321%)	2.27 (49%)	0.957 (127%)	0.916 (32%)
$IO{V}_F$	0.0567 (24.2%)	0.018 (24%)	0.0669 (26.3%)	0.0344 (18%)
σ2 (proportional)	0.066		0.069
σ2 (additive) [nM]	56.02		43.1
Correlations	population	posthoc	population	posthoc
r2 (obs vs predicted)	0.645	0.898	0.672	0.870
med abs pred error	36%	13%	30%	14%

CL = apparent clearance from compartment 1 (plasma); Q = apparent clearance between compartments 1 and 2; V₁ and V₂ = apparent compartment volumes; K_a = first-order absorption rate constant; F= oral bioavailability (fixed = 1) and estimated the variation between wk1 and wk4/5 (IOV). V₁ and V₂ were normalized to the mean of the participant body weights (91.5 kg). RSE = relative standard error. σ² are residual errors; MVOF = minimum value of the NONMEM objective function (−2LL). NE = not estimated. %CV of IIV and IOV was calculated $=\sqrt{e^{{\omega }^2}-1}\times 100$, where ω² is the variance of the log-transformed parameter. r² = linear regression correlation between predicted and observed concentrations. Med abs pred error = median absolute predicted error.